Verition Fund Management LLC
Position in TBPH — Theravance Biopharma, Inc.
CIK 1454027
GREENWICH, CT
Position in TBPH
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$1,785,300
+$1,654,503 QoQ
Shares Held
110,000
+651.0% QoQ
Ownership
0.213%
of shares outstanding
% of Portfolio
0.02%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Dec 2022
5 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in TBPH Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026Verition Fund Management LLC holds $52,210,876 across 39 Biotechnology names. TBPH ranks #8 (3.4% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | EVMN |
Evommune, Inc.
|
549,991 | $12,644,293 | |
| 2 | RVMD |
Revolution Medicines, Inc.
|
110,000 | $10,697,500 | |
| 3 | OCUL |
Ocular Therapeutix, Inc
|
527,338 | $4,466,552 | |
| 4 | XENE |
Xenon Pharmaceuticals Inc.
|
55,000 | $3,198,250 | |
| 5 | ABVX |
Abivax S.A.
|
25,948 | $2,889,309 | |
| 6 | TECH |
BIO-TECHNE Corp
|
53,519 | $2,796,902 | |
| 7 | MLYS |
Mineralys Therapeutics, Inc.
|
95,122 | $2,576,854 | |
| 8 | TBPH |
Theravance Biopharma, Inc.
This page
|
110,000 | $1,785,300 |
All Filings in TBPH
Export CSV
5 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $1,785,300 | 110,000 | Shares | Sole | 2026-05-15 | |
| 2025-03-31 | $130,797 | 14,647 | Shares | Sole | 2025-05-15 | |
| 2024-09-30 | $101,894 | 12,642 | Shares | Sole | 2024-11-14 | |
| 2024-06-30 | $291,169 | 34,336 | Shares | Sole | 2024-08-14 | |
| 2022-12-31 | $126,348 | 11,261 | Shares | Sole | 2023-02-14 | |
| No filing history on record for this holder in this stock. | ||||||